This research report explores R&D investment and decision-making by the pharmaceutical industry during the first half of 2024. To counteract impending losses of exclusivity of drugs that are established revenue drivers, companies have been investing heavily in R&D, doubling down on their most promising assets and candidates, and taking on more development risk earlier in the product lifecycle. While these trends weren’t necessarily prompted by the Inflation Reduction Act (IRA), efforts to optimize investments and development plans fall in line with incentives created by the law and may be amplified by it. Read the brief for more insights.
Recent Work
PACE Growth by the Numbers: October 2026
Program of All-Inclusive Care for the Elderly (PACE) is a capitated health plan that provides comprehensive Medicare and Medicaid covered services to frail, older adults in the community who are eligible for nursing home care. New research from ATI explores the latest enrollment trends and highlights latest opportunities for PACE growth.
Read More
Read More
A Practical Option for States: One-Time Medicaid Reassignment to Support D-SNP Alignment
Beginning January 1, 2030, Dual Eligible Special Needs Plan (D-SNP) enrollment must be fully aligned with Medicaid plan enrollment, and beneficiaries will no longer be able to stay in their current D-SNP. Building on a previous ATI resource, this brief outlines a transitional strategy for states subject to the impending D-SNP enrollment alignment requirements to consider.
Read More
Read More
The Kim Frailty Index and Implications for LEAD ACOs
The Kim Frailty Index (KFI) is a validated, peer-reviewed measure of frailty that uses only healthcare claims data to measure frailty with sufficient accuracy for population-level decision making. The CMS Innovation Center is embedding KFI data into its Long-term Enhanced ACO Design (LEAD) Model as one of the factors used to assess whether a beneficiary qualifies as "High Needs."
Read More
Read More